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Aim: Zygomycosis is a severe angioinvasive infection caused by Zygomycetes. We retrospectively investigated 16 cases of zygomycosis.
Materials and methods: The data of patients, who had been followed between 2004 and 2010 in 8 tertiary-care teaching hospitals,
were reviewed. Demographic characteristics, underlying diseases, and clinical signs and symptoms of the patients, as well as diagnostic
methods, data obtained by radiological imaging methods, and the therapies, were recorded. Therapeutic approaches, antifungal agents
and duration of use, and the characteristics of the cases were identified.
Results: The study included 11 female and 5 male subjects. The most common symptoms and clinical signs were fever (n = 9) and retroorbital pain (n = 7). Rhinocerebral zygomycosis was the most common form. The mean time elapsed for diagnosis was 14.26 ± 13.96
(range: 2–52) days. Antifungal therapy was given to 15 patients (94%). In addition to antifungal therapy, 12 patients underwent surgical
intervention 1 to 4 times. The mean duration of receiving antifungal therapy was 61.4 ± 58.02 (range: 1–180) days. The median duration
of treatment was 62.5 (range: 42–180) days in survivors.
Conclusion: Zygomycosis is an infectious disease with high mortality despite antifungal therapy and surgical interventions.
Key words: Zygomycosis, predisposing factors, Zygomycetes

1. Introduction
The incidence of invasive fungal infections has
increased in recent years. Reasons for this increment
include increased numbers of cases with hematological
malignancies, provisions of myelosuppression with higher
doses of chemotherapy, increased numbers of patients
that undergo organ transplantation, and increased use
of corticosteroids. Therefore, zygomycosis is the other
invasive fungal infection with increased incidence, in
addition to aspergillosis and candidiasis (1,2). Zygomycosis
usually occurs in patients with an underlying factor such
as diabetes mellitus, immunosuppressive therapy, solid
organ and hematopoietic cell transplantation, leukemia,
lymphoma, burns, glomerulonephritis, gastroenteritis,
* Correspondence: onurkaya@sdu.edu.tr
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broad-spectrum antibiotic use, hemodialysis, or
deferoxamine therapy. Although zygomycosis is generally
seen in immunocompromised subjects, it can also be seen
in immunocompetent subjects. The causative pathogen is
usually transported into the body via inhalation through
the nasal sinuses. Moreover, direct spore inoculation
or exposure of skin already compromised by burns or
extensive trauma can lead to the cutaneous form of
zygomycosis (2–8).
Zygomycosis is developed in 5 different clinical pictures:
rhinocerebral, pulmonary, cutaneous, gastrointestinal, and
disseminated. However, different clinical forms such as
osteomyelitis and endocarditis have been rarely mentioned
in the literature. Since the agent microorganism generally
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enters the body via the inhalation route, paranasal sinuses
are the most commonly involved anatomical region in
zygomycosis infection. Unfortunately, symptoms and signs
of the sinusitis in this infection are not pathognomonic
to be differentiated from the clinical picture of sinusitis
caused by other pathogens. Nasal congestion, headache,
maxillary pain, hyposmia, and anosmia may be seen. In
addition, the presence of necrotic scarring in the nasal
cavity and necrotic facial lesions indicate an angioinvasive
infection (8–12).
Zygomycosis still has high mortality today, despite
early diagnosis and treatment. Therefore, there is a need
for new data about the treatment of this disease. The aim
of this study was to analyze demographic characteristics,
underlying diseases, and clinical and treatment results of
patients diagnosed with zygomycosis in 8 tertiary-care
teaching hospitals between 2004 and 2010.
2. Materials and methods
The data of patients who had been followed between
2004 and 2010 in 8 tertiary-care teaching hospitals were
reviewed. Demographic characteristics, underlying
diseases, and clinical signs and symptoms of the patients, as
well as diagnostic methods, data obtained by radiological
imaging methods, and the therapies, were recorded.
Diagnosis of zygomycosis was made in accordance with
the criteria issued by European Organization for Research
and Treatment of Cancer/Mycoses Study Group (13). The
clinical forms of zygomycosis have been defined based on
the involved organ: rhinocerebral (rhino-orbito-cerebral,
rhino-orbital), cutaneous, pulmonary, gastrointestinal,
and disseminated (3,9). As well as the clinical findings,
radiological imaging methods (computed tomography and
magnetic resonance imaging) and endoscopic methods
(rhinoscopy, gastrointestinal endoscopy) were used to
detect the localization of the infections. Therapeutic
approaches, antifungal agents and duration of use, and the
characteristics of the cases were identified. The authors
thought that ethical approval was not required for this
retrospective study.
3. Results
The study included 11 female and 5 male subjects. The mean
age was 52.50 ± 14.55 (range: 22–68) years. The majority of
the patients (n = 15, 94%) were immunocompromised and
most of them had type 2 diabetes mellitus (n = 10, 62.5%).
Seven patients had received corticosteroid treatment. The
most common symptoms and clinical signs were fever
(n = 9) and retro-orbital pain (n = 7). Rhinocerebral
zygomycosis was the most common form (Table 1).
Mycological cultures were performed in 14 patients and
half of them had a positive culture. Isolated pathogens
included Rhizopus spp. (n = 4), Mucor spp. (n = 2), and

Rhizomucor spp. (n = 1). Characteristics of underlying
conditions, clinical forms, and management, as well as the
data of the patients, are given in Table 2.
The diagnosis was made based on culture positivity
alone in 2 (12.5%) of the cases, whereas it was made based
on the histopathological findings in 9 (56.25%) and based
on both culture positivity and histopathological findings in
5 (31.25%) cases. Aspergillus flavus was found as a second
agent in 2 cases. The mean time elapsed for diagnosis was
14.26 ± 13.96 (range: 2–52) days.
The mean duration of receiving antifungal therapy
was 61.4 ± 58.02 (range: 1–180) days. On the other hand,
the median duration of treatment was 62.5 (range: 42–
180) days in survivors. Overall, a favorable response was
observed in 6 patients (37.5%). Antifungal therapy was
given to 15 patients (94%) (Table 3). One patient (case 8)
received voriconazole for aspergillosis. On the 25th day
of treatment therapy was switched from voriconazole to
liposomal amphotericin B (L-AmB) because the tissue
samples were consistent with both zygomycosis and
aspergillosis. In addition to antifungal therapy, 12 patients
underwent surgical intervention 1 to 4 times. Local AmB
irrigation was tried in 4 patients.
4. Discussion
Zygomycosis is associated with several risk factors.
Diabetes mellitus is one of the most important risk factors
for zygomycosis (5). Neutrophil dysfunction is a common
condition in the diabetic patient, especially in the setting of
diabetic ketoacidosis. In the current study, type 2 diabetes
mellitus was present in 10 of 16 patients, 2 of which were
steroid-induced, and it was the most common underlying
disease (Table 2). Generally, the rhinocerebral form is
seen in diabetic patients (14). In the present study, almost
all diabetic patients showed sinus involvement, and 90%
had the rhinocerebral form. The present study revealed
that corticosteroid use was the most common comorbid
condition that accompanied diabetes mellitus. Although
mortality rates change in the presence of comorbid
conditions that accompany diabetes mellitus, statistical
analysis could not be done due to the limited number of
patients. Roden et al. (5) found the mortality rate to be
44% among diabetic patients diagnosed with zygomycosis.
In our study, the mortality rate was found to be 80%
among diabetic patients regardless of comorbid disease.
The difference might be explained by the higher mortality
rates observed in rhinocerebral zygomycosis (62%) in the
current study and the rate of disseminated disease (100%)
in the current study, as well as other factors.
Another risk factor is renal failure. Deferoxamine
use in such patients is likely an important risk factor
for zygomycosis development. Deferoxamine binds to
the host iron and is presented to the microorganism as
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F, 64

F, 50

M, 37

F, 27

F, 62

F, 61

M, 60

F, 61

F, 63

M, 63

F, 50

F, 22

M, 55

M, 63

F, 68

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

ROC

Headache, diplopia,
dysphagia

Retro-orbital pain,
facial palsy, orbital cellulitis

Retro-orbital pain, headache, unilateral facial
ROC
swelling, necrotic scar in the nasal cavity

Retro-orbital pain, fever, headache,
unilateral facial swelling, orbital cellulitis

DM

DM,
corticosteroid

DM,
corticosteroid

DM, corticosteroid,
AML, neutropenia,
broad spectrum
antibiotic

ROC

RO

Retro-orbital pain, fever,
unilateral facial swelling

Retro-orbital pain,
facial palsy, headache, unilateral facial
swelling, orbital cellulitis, proptosis

Retro-orbital pain,
fever, headache

DM, cirrhosis,
broad spectrum
antibiotic

DM,
CRF

DM,
CRF, surgery

Disseminated

RO

Disseminated

Pulmonary

Disseminated

Gastrointestinal

Aplastic anemia,
Fever,
broad spectrum
unilateral facial swelling
antibiotic, neutropenia

Fever, dyspnea, orbital cellulitis, proptosis,
blurred vision, retro-orbital pain

Fever, abdominal pain

Corticosteroid,
MCL, broad
spectrum antibiotic

MDS,
neutropenia

Melena

Cirrhosis,
corticosteroid, SOT

Fever, cough, sputum

Ptosis, proptosis

DM*,
corticosteroid, CRF

Prostate cancer

ROC

Fever, diplopia, blurred vision, unilateral
facial swelling, orbital cellulitis, proptosis

DM
ROC

ROC

Purulent nasal discharge, orbital cellulitis,
proptosis

DM*, corticosteroid,
surgery

Cutaneous

2 × 2 cm diameter ulcer of the left thumb

None

RO

ROC

Clinical
forms

Symptoms and signs

Underlying
conditions

–

Rhizomucor spp.,
Aspergillus flavus

Negative

Negative

Rhizopus spp.

+

+

+

+

+

Rhizopus spp.

Negative

+

+

**

+

Not performed

Not performed

Aspergillus flavus

Mucor spp.

+

+

Rhizopus spp.
Mucor spp.

+

+

+

+

Pathology
(findings of
zygomycosis)

Negative

Negative

Rhizopus spp.

Negative

Fungal
cultures

Proven

Proven

Proven

Proven

Proven

Proven

Proven

Proven

Probable

Proven

Proven

Proven

Proven

Proven

Proven

Proven

Diagnosis

Antifungal +
surgery

Antifungal +
surgery +
AmB irrigation

Antifungal +
surgery

Antifungal

15

5

7

21

5

3

Antifungal +
surgery
Antifungal

12

2

33

15

12

4 years

8

10

14

52

Time elapsed
for diagnosis
(days)

–

Antifungal

Antifungal +
surgery

Antifungal +
surgery

Antifungal +
surgery
Antifungal +
surgery

Antifungal +
surgery +
AmB irrigation

Antifungal +
surgery

Antifungal +
surgery +
AmB irrigation
Antifungal +
surgery +
AmB irrigation

Management

120

25

12

57

7

68

–

42

1

179

180

42

36

53

7

92

Treatment
duration
(days)

Death

Death

Death

Alive

Death

Alive

Death

Alive

Death

Alive

Alive

Alive

Death

Death

Death

Death

Outcome

F: Female, M: male, DM: diabetes mellitus, DM*: corticosteroid-induced diabetes mellitus, CRF: chronic renal failure, AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, MCL: mantle cell lymphoma, SOT: solid organ
transplant, ROC: rhino-orbito-cerebral, RO: rhino-orbital, AmB: amphotericin B. **: Histologically, aspergillosis, and mucormycosis hyphae were detected in the specimen.

F, 34

1

Sex,
age

Table 1. Age, sex, predisposing conditions, symptoms and signs, clinical forms, cultures, pathology, and treatment managements of 16 cases of zygomycosis.
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Table 2. Underlying conditions, clinical forms, and treatments of 16 patients, 10 of whom died.
n (%)

Mortality n (%)

10 (62.5)

8 (80)

only

2 (20)**

1 (50)

and corticosteroid use

5 (50)**

4 (80)

and chronic renal failure

3 (30)**

3 (100)

and broad spectrum antibiotic use

2 (20)**

2 (100)

and surgery

2 (20)**

1 (50)

and cirrhosis

1 (10)**

1 (100)

Hematological disorders

4 (25)***

3 (75)

and neutropenia

3 (75)***

2 (66.7)

and broad spectrum antibiotic use

3 (75)***

2 (66.7)

and corticosteroid use

2 (50)***

2 (100)

Solid tumor

1 (6.3)

0 (0)

SOT*, corticosteroid use, cirrhosis

1 (6.3)

0 (0)

Rhino-orbito-cerebral

7 (43.75)

5 (71.4)

Rhino-orbital

3 (18.8)

2 (66.7)

Disseminated

3 (18.8)

3 (100)

Pulmonary

1 (6.3)

0 (0)

Cutaneous

1 (6.3)

0 (0)

Gastrointestinal

1 (6.3)

0 (0)

Antifungal therapy alone

3 (18.8)

1 (33.3)

Antifungal therapy + surgery

8 (50)

4 (50)

Antifungal therapy + surgery + irrigation with AmB

4 (25)

4 (100)

No therapy (postmortem diagnosis)

1 (6.3)

1 (100)

Underlying conditions*
Diabetes mellitus

Clinical forms

Treatment

*: There were more than 2 conditions in some patients.
**: Calculated for 10 patients.
*** Calculated for 4 patients.
SOT: Solid organ transplant recipient, AmB: amphotericin B deoxycholate.

siderophores, inducing sporulation and development of
zygomycosis (10,15). Pulmonary zygomycosis is seen in
patients with renal failure (16). Chronic renal failure was
present in 3 of the cases: 2 patients with the rhino-orbitocerebral form and 1 patient with the disseminated form,
all of whom died. The study conducted by Roden et al.
(5) showed that 36 of 929 zygomycosis patients had renal

failure and 89% died; multivariate analysis revealed that
renal failure increased the mortality risk by 7 times.
Prolonged neutropenia is known to increase the risk for
zygomycosis due to its reduced phagocytic characteristic.
In the literature, more than 70% of zygomycosis patients
have neutropenia, and the median neutropenia duration
is between 12 and 16 days (17). Pulmonary zygomycosis

479

KAYA et al. / Turk J Med Sci
Table 3. Details of antifungal therapy.
Patient no.

Antifungal therapy

Total antifungal therapy
duration (days)

1

AmB 1 mg kg–1 day–1 (8 days) then L-AmB 5–10 mg kg–1 day–1

92

2

AmB 1 mg kg–1 day–1 (7 days) then L-AmB 5 mg kg–1 day–1

7

3

AmB 1 mg kg day (23 days) then L-AmB 10 mg kg day

53

4

AmB 1 mg kg day (4 days) then L-AmB 5 mg kg day

36

5

AmB 1 mg kg–1 day–1

42

6

AmB 1 mg kg–1 day–1 (1 day) then L-AmB 5 mg kg–1 day–1

180

7

AmB 1 mg kg day (6 days) then L-AmB 5 mg kg day
(93 days) then posaconazole 800 mg day–1

179

8

Voriconazole (25 days, for aspergillosis) then L-AmB 5 mg kg–1 day–1

2

9

L-AmB 5 mg kg day

42

10

–

–

11

AmB 1 mg kg–1 day–1 ( 1 day) then L-AmB 5 mg kg–1 day–1
(7 days) then posaconazole 800 mg day–1

68

12

AmB 1 mg kg–1 day–1 (1 day) then L-AmB 5 mg kg–1 day–1

13

AmB 1 mg kg day (8 days) then ABLC 5–9 mg kg day

57

14

L-AmB 3 mg kg–1 day–1

12

15

AmB 1 mg kg–1 day–1 (1 day) then L-AmB 5 mg kg–1 day–1

25

16

L-AmB 3 mg kg day

120

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

–1

7
–1

AmB: Amphotericin B deoxycholate, L-AmB: liposomal amphotericin B, ABLC: amphotericin B lipid complex.

is the most common clinical picture in neutropenic
patients (18). In our study, neutropenia was found in 3 of
the 4 patients with hematologic malignancy; 2 displayed
the rhino-orbital form and 1 displayed the disseminated
form. Neutrophils play a substantial role in preventing
development of invasive fungal infection (17). Therefore,
they form the most important part of the cellular host
defense against zygomycosis (19).
Corticosteroid use is another risk factor for the
development of zygomycosis. It has been shown in
experimental models that corticosteroids suppress
phagocytic activities of macrophages, leading to a tendency
toward zygomycosis infection (20). Corticosteroids were
used in 7 of 16 patients, 6 of whom died.
An association has been revealed between zygomycosis
and the use of voriconazole, itraconazole, and caspofungin
for treatment or prophylaxis (1,21). In the present study,
none of the patients had used an antifungal agent within
the last year, whereas 4 had received broad-spectrum
antibiotic therapy. Liver cirrhosis and surgery also create
a predisposition to the development of zygomycosis
(5,22,23).
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Rhinocerebral zygomycosis is characterized by nasal and
paranasal sinus involvement as well as orbital, cavernous sinus,
and cerebral involvement (9). In our study, the rhinocerebral
form (including the rhino-orbital form) was identified in
10 patients, 7 of whom died. Concerning the remaining
3 cases, the time until diagnosis was 12, 15, and 21 days,
respectively. Debridement was performed in 2 patients along
with antifungal therapy; 1 patient received antifungal therapy
alone. Various studies have mentioned high mortality rates
concerning rhinocerebral involvement and the association
between late diagnosis and mortality (9,24).
Pulmonary zygomycosis most commonly occurs
in hematopoietic stem cell recipients and diabetic and
leukemic patients who are receiving chemotherapy (19,25).
Pulmonary zygomycosis usually presents as a rapidly
progressing pneumonia. Nonetheless, symptoms and
signs seen in early periods, such as fever, cough, thoracic
pain, and dyspnea, are not specific. However, pulmonary
zygomycosis should be considered in the case of prolonged
fever and unresponsiveness to broad-spectrum antibiotics
in the risk-group patients. Hemoptysis may also be seen
and can even result in mortality if large vessel erosion has
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occurred. In the present study, one patient had pulmonary
zygomycosis with a solid tumor. The patient presented
with fever, cough, and sputum; the thorax computed
tomography showed a cavity of 6 × 6 cm in the upper lobe
of the right lung. Rhizopus spp. was grown in the sample
obtained and was consistent with zygomycosis upon
histopathological examination. In addition to the surgical
intervention, the patient received L-AmB at a dose of 5
mg/kg daily as antifungal therapy; however, the therapy
was discontinued on the seventh day and posaconazole
was commenced at a dose of 800 mg/day per os for 60 days.
The disseminated form is usually identified during
postmortem evaluation of cases with deep immune
suppression (9). In the present study, one patient was
diagnosed with disseminated zygomycosis during
postmortem evaluation. The patient had been diagnosed
with mantle cell lymphoma and developed neutropenic
fever on the 10th day of chemotherapy. She had abdominal
pain and received broad-spectrum antibiotic therapy.
The patient died before antifungal therapy could be
started. However, postmortem examination revealed
disseminated zygomycosis. The mortality rate is almost
100% in disseminated cases; in the present study, all of the
3 patients with the disseminated type died. Disseminated
zygomycosis infection usually results from the extension
of invasive pulmonary disease (19). In one of our cases,
the clinical picture appeared as neutropenic fever and
pneumonia with detection of necrotic tissues a few days
later in the nasal region. Rhizomucor spp. were isolated
from both the tissue sample from the nasal region and
bronchoalveolar lavage fluid.
The incidence of the gastrointestinal form of
zygomycosis is approximately 7%, with a mortality
rate of 85% (5). The stomach, colon, and ileum are
the most commonly involved sites. The symptoms
vary depending on the involved site. Nonetheless, the
most common symptoms include abdominal pain and
distension accompanied by nausea and vomiting (19). The
present study includes one patient with gastrointestinal
zygomycosis. The initial complaint of the case was melena;
a sample was obtained during endoscopic procedure
from the black-red mottling around the ulcer, and hyphae
consistent with zygomycosis were seen upon pathological
evaluation of the material. Antifungal therapy was
commenced for the patient. No other fungal infection
focus was detected via other imaging methods. After 42
days of antifungal therapy, the patient underwent a control
endoscopic evaluation, and it was observed that the lesion
had disappeared.
Primary cutaneous zygomycosis can be developed
even in immunocompetent subjects after traumas (motor
vehicle accidents) and burns (9). The disease may present
with slow or fulminant progress depending on the clinical

condition. Cutaneous disease may lead to necrotizing
fasciitis, which has a mortality rate of 80%. However,
isolated cutaneous zygomycosis has a favorable prognosis
and low mortality rate if surgical debridement is done
(19,26). The present cutaneous case had no predisposing
factors other than trauma. The clinical picture appeared
as a cutaneous infection with a 4-year history. The patient
was cured with antifungal therapy and surgery.
The zygomycosis case series showed that males are
involved more than females. Various researchers attributed
this discrepancy to the potential protective effect of estrogen
(5). In the present study, 11 of 16 patients were female and 5
were male. This inconsistent finding with the literature can
be attributed to the limited number of patients. Despite the
availability of modern laboratory methods, the diagnosis
of zygomycosis is difficult. Unfortunately, 4% of cases are
diagnosed in the postmortem period; 6% can be diagnosed
24 h before death via culture and histological examination
(25). In the present study, culture positivity may remain at
a rate of 50% in the diagnosis of zygomycosis. The most
commonly isolated agents include Rhizopus spp. and
Mucor spp. (7). These were the most commonly isolated
agents in the current study. Aspergillus flavus was isolated
in the mycological cultures of 2 cases in addition to the
zygomycosis agents. Previous literature has addressed the
concomitance of these 2 microorganisms (27–29).
The mean time elapsed for the diagnosis was 14.26 ±
13.96 days. Since it could change the mean value, the 4-year
duration of the cutaneous case was not included when the
mean time was calculated. As mentioned, the mortality
rate is low in early-diagnosed cases (24). In the present
study, the time span from the onset of the symptoms to
the diagnosis was between 2 and 21 days among survivors
and between 5 and 52 days among those who died. When
considered on a case-by-case basis, the time elapsed for
the diagnosis was nearly the same in both groups.
The treatment of zygomycosis comprises 3 main factors:
antifungal therapy, surgical debridement, and relieving
underlying metabolic problems or improving immune
status (19). Before the availability of AmB for the treatment
of zygomycosis, the survival rate was less than 6%; today,
it has reached 60% with the use of AmB lipid formulations
in both experimental and clinical case series (30–33). In
addition to AmB preparations, posaconazole is another
agent that has shown in vitro efficacy against Zygomycetes
and that has been successfully used in the treatment of
zygomycosis cases in 2 clinical trials (34–36). The rates
of improvement using 800 mg/day posaconazole were
60% and 79%, respectively, in the above-mentioned trials.
Currently, it is recommended as salvage therapy. In the
present study, posaconazole was used as salvage therapy in
2 cases, and successful outcomes were obtained. Although
therapy duration in zygomycosis varies depending on the
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case, it should continue for at least 6 to 8 weeks (18). In
the present study, the mean therapy duration was 62.5 days
(approximately 9 weeks) among survivors.
The success rate of antifungal therapy alone is low due
to antifungal drugs passing into the tissue (37). In the
present study, the success rate of antifungal therapy alone
was 33%. The mortality rate decreases with appropriate
surgical debridement; a systemic antifungal agent was used
in the present study. Surgical intervention is an important
factor in the treatment of zygomycosis. Aggressive surgical
intervention of infected craniofacial tissues in the early
period in cases of rhinocerebral zygomycosis is important
for successful therapy (38).
Since there could be problems with antifungal agents
passing into the related anatomical area due to massive

amounts of necrotic tissue, local AmB application (in
addition to surgical intervention and systemic antifungal
therapy) was administered in 4 patients, all of whom died.
Such a high mortality rate despite appropriate surgical
debridement and appropriate antifungal therapy might
have resulted from the limited number of cases. Therefore,
more studies on AmB irrigation are needed.
In conclusion, diabetes mellitus and corticosteroid
use are common underlying conditions in zygomycosis.
Zygomycosis is an infectious disease with high mortality
despite antifungal therapy and surgical interventions.
A high degree of clinical suspicion in patients at risk of
zygomycosis, together with aggressive diagnostic efforts as
well as prompt initiation of medical and surgical therapy,
are of utmost importance in order to improve outcomes.
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